Medical devices, healthcare technology and the business of care
PMA approval · P010014

OXFORD(TM) MENISCAL UNICOMPARTMENTAL KNEE SYSTEM

Biomet Manufacturing Corp · Decision date Apr 21, 2004

MEDTECHLEDGER EXPLANATIONP010014

What did the FDA approve?

FDA approved the Oxford Meniscal Unicompartmental Knee System (Phase 3) on April 21, 2004. The approval statement describes the device as indicated for patients with osteoarthritis or avascular necrosis limited to the medial compartment of the knee, with implantation intended to use bone cement.

The device is classified as a semi-constrained, metal/polymer, mobile-bearing unicompartmental femorotibial knee prosthesis. The record does not include a supplement type or supplement reason, so no change to a prior approval is described. The statement reports the intended use but does not independently establish safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE OXFORD MENISCAL UNICOMPARTMENTAL KNEE SYSTEM (PHASE 3). THE DEVICE IS INDICATED FOR USE IN PATIENTS WITH OSTEOARTHRITIS OR AVASCULAR NECROSIS LIMITED TO THE MEDIAL COMPARTMENT OF THE KNEE AND INTENDED TO BE IMPLANTED WITH BONE CEMENT.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Apr 21, 2004

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010014
Regulatory pathway
Premarket approval application
Product code
NRA
Decision code
APPR
Decision date
Apr 21, 2004
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, femorotibial, unicompartmental, semi-constrained, metal/polymer, mobile bearing.

Product code
NRA
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P010014 received

    Application receipt date recorded by FDA.

  2. P010014 · FDA decision

    APPR

  3. P010014/S118 · Related supplement

    Oxford Partial Knee Anatomic Vivacit-E Meniscal Bearings

  4. P010014/S119 · Related supplement

    Cementless Oxford Partial Knee System

  5. P010014/S120 · Related supplement

    Oxford Partial Knee System

Timeline entries are records held by MedtechLedger for P010014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010014

Product / regulatory recordCompanyPathwayDecision dateSource
Biomet Manufacturing CorpPMA supplementSep 1, 2026FDA
Biomet Manufacturing CorpPMA supplementOct 6, 2026FDA
Biomet Manufacturing CorpPMA supplementOct 26, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biomet Manufacturing Corp

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
56 E. Bell Dr.,, P.O. Box 587, Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records